Status:
COMPLETED
CJD (Creutzfeldt-Jakob Disease) Quinacrine Study
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Creutzfeldt-Jakob Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical trial is to determine the effectiveness of the medication quinacrine on survival in sporadic Creutzfeldt-Jakob disease (sCJD).
Detailed Description
Creutzfeldt-Jakob disease (CJD)is a rapidly progressive, invariably fatal and untreatable neurodegenerative disease with a mean duration of about eight months. Beyond the debilitating cognitive and mo...
Eligibility Criteria
Inclusion
- Diagnosis of probable or definite sCJD: Definite--biopsy confirmed sCJD; Probable--a progressive dementia with either a typical EEG or a typical MRI consistent with sCJD, and at least two of the following clinical features: myoclonus, pyramidal or extrapyramidal signs, visual symptoms, cerebellar signs, akinetic mutism, other focal higher cortical neurologic signs (e.g. neglect, apraxia, aphasia)
- 18 years of age or older
- Able to swallow
- Able to follow simple one-step commands
- Have had a brain MRI within 6 months and an EEG within 3 months ruling out other etiologies such as masses, strokes, or non-convulsive status epilepticus
- Consent to autopsy in the event of their death during or after the study
Exclusion
- History of other significant or life-threatening disease, including: cancer; end-stage liver or renal disease; severe heart disease
- History of other disease requiring regular supportive care
- Liver disease
- Active alcoholism
- Bone marrow suppression
- Severe hypotension
- Severe psoriasis
- Poorly controlled diabetes
- Women who are pregnant or breast-feeding
- Men, or women of childbearing age, not practicing reliable contraception
- Serious allergies to quinacrine or other acridines
- Current or recent use of quinacrine (within 6 months)
- \< 18 years of age
- Any other contraindication to taking quinacrine
- Genetic form of prion disease is identified prior to study enrollment
- Current use of anti-arrhythmics (at discretion of investigator)
- G6PD (Glucose 6-Phosphate Dehydrogenase) deficiency (at discretion of investigator)
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT00183092
Start Date
April 1 2005
End Date
June 1 2012
Last Update
June 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143